Sun Pharmaceutical Industries, Inc.; Withdrawal of Approval of 28 Abbreviated New Drug Applications
The Food and Drug Administration (FDA) is withdrawing approval of 28 abbreviated new drug applications held by Sun Pharmaceutical Industries, Inc. (Sun Pharmaceutical), U.S. Age...
The Food and Drug Administration (FDA) is withdrawing approval of 28 abbreviated new drug applications held by Sun Pharmaceutical Industries, Inc. (Sun Pharmaceutical), U.S. Agent for Sun Pharmaceutical Industries Limited, 270 Prospect Plains Rd., Cranbury, NJ 08512. The drug products are no longer marketed, and Sun Pharmaceutical has requested that the approval of the applications be withdrawn.
DATES:
January 19, 2017.
FOR FURTHER INFORMATION CONTACT:
Florine P. Purdie, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6248, Silver Spring, MD 20993-0002, 301-796-3601.
SUPPLEMENTARY INFORMATION:
The applications listed in the table in this document are no longer marketed, and Sun Pharmaceutical has requested that FDA withdraw approval of the applications. The company has also, by its request, waived its opportunity for a hearing.
Application No.
Drug
065007
Cephalexin Capsules USP, Equivalent to (EQ) 250 milligrams (mg) base and EQ 500 mg base.
065016
Amoxicillin Capsules USP, 250 mg and 500 mg.
065021
Amoxicillin Tablets USP (Chewable), 125 mg and 250 mg.
065059
Amoxicillin Tablets USP, 500 mg and 875 mg.
065060
Amoxicillin Tablets USP (Chewable), 200 mg and 400 mg.
065081
Cephalexin for Oral Suspension USP, EQ 125 mg base/5 milliliters (mL) and EQ 250 mg base/5 mL.
065082
Cefpodoxime Proxetil for Oral Suspension USP, EQ 50 mg base/5 mL and EQ 100 mg base/5 mL.
065083
Cefpodoxime Proxetil Tablets USP, EQ 100 mg base and EQ 200 mg base.
Gabapentin Capsules USP, 100 mg, 300 mg, and 400 mg.
076739
Fosinopril Sodium and Hydrochlorothiazide Tablets USP, 10 mg/12.5 mg and 20 mg/12.5 mg.
Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research, by the Commissioner, approval of the applications listed in the table, and all amendments and supplements thereto, is hereby withdrawn, effective January 19, 2017.
Use this for formal legal and research references to the published document.
81 FR 92821
Web Citation
Suggested Web Citation
Use this when citing the archival web version of the document.
“Sun Pharmaceutical Industries, Inc.; Withdrawal of Approval of 28 Abbreviated New Drug Applications,” thefederalregister.org (December 20, 2016), https://thefederalregister.org/documents/2016-30623/sun-pharmaceutical-industries-inc-withdrawal-of-approval-of-28-abbreviated-new-drug-applications.